RxDoctor Payments DataLook up a doctor →

Bharat Gummadi, MD

Interventional Cardiology · Jacksonville, FLNPI 1033141692

Payments from drug & device makers

$338,933in general payments, 2019–2025

Across 1,294 payments — averaging $261.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$99K
  • Medtronic$90K
  • Amgen$82K
  • Shockwave Medical, Inc$29K
  • Abbott$7K
  • Abiomed$6K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$6,6004%
  • Speaking & faculty fees$95,01262%
  • Travel & lodging$15,07510%
  • Food & beverage$35,78923%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS314$99,232
Medtronic(2 entities)77$90,240
Amgen130$81,940
Shockwave Medical, Inc124$28,746
Abbott86$7,321
Abiomed77$6,337
Penumbra, Inc.75$5,899
Inari Medical, Inc.45$5,471
Edwards Lifesciences59$4,319
Boston Scientific24$1,035
Cardiva Medical, Inc.39$692
Johnson & Johnson28$650
Stryker15$555
Endologix LLC8$497
Teleflex LLC6$466
AstraZeneca21$462
Cardiovascular Systems Inc.6$350
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)18$347
Philips North America LLC3$309
Cvrx, Inc.4$297
Heartflow, Inc.2$295
Angiodynamics, Inc.4$274
Siemens Medical Solutions USA, Inc.3$263
E.r. Squibb & Sons, L.L.C.19$261
Novartis14$229
Pfizer12$203
Actelion Pharmaceuticals US, Inc.5$174
Contego Medical, Inc2$168
Merck8$147
W. L. Gore & Associates, Inc.2$141
Limflow Inc.1$135
Boehringer Ingelheim6$132
Recor Medical Inc2$123
Sanofi-aventis U.S. LLC7$121
ZOLL Circulation Inc1$120
Bard Peripheral Vascular, Inc.5$90
Astellas Pharma US Inc4$85
Imperative Care, Inc3$84
Kestra Medical Technology Services, Inc.3$84
Esperion Therapeutics, Inc.4$75
Acist Medical Systems, Inc.2$66
Biosense Webster, Inc.1$52
Kiniksa Pharmaceuticals, Ltd.3$46
Terumo Medical Corporation2$40
Bayer2$37
GE HealthCare2$35
Kiniksa Pharmaceuticals International, PLC1$29
Endotronix, Inc.1$27
Chiesi USA, Inc.2$26
Regeneron Healthcare Solutions, Inc.1$24
Tactile Systems Technology Inc1$23
Alnylam Pharmaceuticals Inc.1$22
Avinger Inc.1$18
Novo Nordisk1$18
Altathera Pharmaceuticals LLC1$18
Ionis Pharmaceuticals, Inc.1$16
Gilead1$15
Elutia, Inc.1$15
Cook Medical LLC1$14
Venclose Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$338,933 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$430,408
Medicare patients
1,733
Services billed
4,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$150,521
Repatha SureclickEvolocumab72$72,645
EntrestoSacubitril/Valsartan49$61,732
BrilintaTicagrelor99$46,897
Repatha PushtronexEvolocumab36$26,019
XareltoRivaroxaban20$24,920
Repatha SyringeEvolocumab11$12,464
Ranolazine ErRanolazine82$8,655
Metoprolol Succinate289$3,767
ClopidogrelClopidogrel Bisulfate340$3,219
Prasugrel Hcl33$2,080
Atorvastatin Calcium180$1,845
Rosuvastatin Calcium142$1,390
Amlodipine Besylate87$780
Ezetimibe52$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$150,521153 claims
NovartisEntresto$229$61,73249 claims
AstraZenecaBrilinta$462$46,89799 claims
Johnson & JohnsonXarelto$650$24,92020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →